Physician profile
Derick Garey Holt
NPI 1386886729
$636.06
in general payments reported to CMS, 2019-2025
9 companies · $151 in 2025
The $151 reported for 2025 was more than what a typical Pediatric Ophthalmology and Strabismus Specialist provider received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $13.49 · 2021: $34.39 · 2022: $69.95 · 2023: $119 · 2024: $71.36 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $182.09 | 2021-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $139.33 | 2019-2021 | |
| Abbvie INC. | $98.54 | 2025 | |
| Amgen INC. | $61.63 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $56.51 | 2019 | |
| Alcon Vision LLC | $37.21 | 2023-2025 | Rocklatan, Tryptyr |
| Dompe US, INC. | $23.43 | 2024 | Oxervate |
| Mallinckrodt Hospital Products INC. | $21.56 | 2025 | Acthar |
| Travere Therapeutics, INC. | $15.76 | 2019-2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derick Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.